Free Trial
OTCMKTS:PBIO

Pressure BioSciences (PBIO) Stock Price, News & Analysis

Pressure BioSciences logo
$0.0045 -0.01 (-66.67%)
As of 04/2/2025 02:48 PM Eastern

About Pressure BioSciences Stock (OTCMKTS:PBIO)

Key Stats

Today's Range
$0.0045
$0.0045
50-Day Range
$0.0036
$0.0135
52-Week Range
$0.00
$0.31
Volume
223 shs
Average Volume
7,616 shs
Market Capitalization
$193,351.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

Remove Ads

Pressure BioSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

PBIO MarketRank™: 

Pressure BioSciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pressure BioSciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pressure BioSciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pressure BioSciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.00% of the float of Pressure BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pressure BioSciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Pressure BioSciences does not currently pay a dividend.

  • Dividend Growth

    Pressure BioSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the float of Pressure BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pressure BioSciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Pressure BioSciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Pressure BioSciences this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pressure BioSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.80% of the stock of Pressure BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.02% of the stock of Pressure BioSciences is held by institutions.

  • Read more about Pressure BioSciences' insider trading history.
Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Stock News Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
The big blood pressure experiment
See More Headlines

PBIO Stock Analysis - Frequently Asked Questions

Pressure BioSciences' stock was trading at $0.0035 at the start of the year. Since then, PBIO stock has increased by 28.6% and is now trading at $0.0045.
View the best growth stocks for 2025 here
.

Pressure BioSciences, Inc. (OTCMKTS:PBIO) issued its earnings results on Friday, February, 7th. The company reported ($0.15) EPS for the quarter.

Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pressure BioSciences investors own include Hydrofarm Holdings Group (HYFM), Advanced Micro Devices (AMD), Monaker Group (MKGI), Meta Materials (MMAT), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP) and Novavax (NVAX).

Company Calendar

Last Earnings
2/07/2025
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
OTCMKTS:PBIO
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,310,000.00
Net Margins
-2,053.81%
Pretax Margin
-2,053.68%

Debt

Sales & Book Value

Annual Sales
$1.98 million
Price / Cash Flow
N/A
Book Value
($1.29) per share
Price / Book
0.00

Miscellaneous

Free Float
36,543,000
Market Cap
$193,351.50
Optionable
Not Optionable
Beta
-0.41

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:PBIO) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners